Thymic tumors and results of radiotherapy

Publication date: March–April 2018
Source:Reports of Practical Oncology & Radiotherapy, Volume 23, Issue 2
Author(s): Sureyya Sarıhan, Ahmet Sami Bayram, Cengiz Gebitekin, Omer Yerci, Deniz Sıgırlı
AimThe aim of this study was to evaluate thymic epithelial tumors (TETs) for treatment outcomes and prognostic factors on survival.BackgroundTETs are very rare neoplasms and multidisciplinary approach is recommended according to prognostic factors.Materials and methodsBetween 1995 and 2013, 31 patients were treated with median 5400cGy (range: 1620–6596cGy) radiotherapy (RT). Eleven patients received adjuvant or concurrent chemotherapy. There were 25 thymomas, 4 thymic carcinomas and 2 thymic neuroendocrin carcinomas. According to Masaoka, staging and WHO classification, cases were divided to good (n: 10), moderate (n: 9) and poor (n: 12) prognostic risk groups. Survival was calculated from diagnosis.ResultsIn January 2016, 22 cases were alive with median 51.5 months (range: 2–170.5) follow-up. Recurrences were observed in 29% of patients in median 29.5 months (range: 6.5–105). Local control, mean overall (OS) and disease-free survival (DFS) rates were 86%, 119 and 116 months, respectively. There was a significant difference for R0 vs. R+ resection (81% vs. 43%, p=0.06, and 69% vs. 46%, p=0.05), Masaoka stage I–II vs. III–IV (75% vs. 52%, p=0.001, and 75% vs. 37%, p<0.001), and also prognostic risk groups (100% vs. 89% vs. 48%, p=0.003, and 100% vs. 87% vs. 27%, p=0.004) in terms of 5-year OS and DFS, respectively.ConclusionIn our study, prognostic risk stratification was shown to be a significant predictor of survival. There is a need to investigate subgroups that may or may not benefit from adjuvant RT.



http://ift.tt/2HHjOSS